Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPS
Equities analysts expect that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will announce earnings of $0.25 per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. The lowest EPS estimate is $0.23 and the highest is $0.27. Sucampo Pharmaceuticals posted earnings of $0.28 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 10.7%. The firm is scheduled to announce its next earnings results on Wednesday, November 8th.
On average, analysts expect that Sucampo Pharmaceuticals will report full-year earnings of $1.01 per share for the current financial year, with EPS estimates ranging from $0.98 to $1.04. For the next fiscal year, analysts forecast that the business will report earnings of $1.06 per share, with EPS estimates ranging from $0.98 to $1.14. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The company’s revenue was up 15.3% compared to the same quarter last year.
SCMP has been the topic of a number of research reports. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Maxim Group set a $23.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. TheStreet lowered shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Finally, Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $17.29.
In other news, insider Jones W. Bryan purchased 4,700 shares of the company’s stock in a transaction on Friday, August 4th. The shares were purchased at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now owns 4,700 shares of the company’s stock, valued at approximately $49,820. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. Corporate insiders own 4.13% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of SCMP. Great West Life Assurance Co. Can raised its position in Sucampo Pharmaceuticals by 900.8% during the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 32,203 shares in the last quarter. Bank of New York Mellon Corp raised its position in Sucampo Pharmaceuticals by 107.3% during the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after acquiring an additional 190,292 shares in the last quarter. Comerica Bank bought a new stake in Sucampo Pharmaceuticals during the first quarter worth $275,000. Karp Capital Management Corp bought a new stake in Sucampo Pharmaceuticals during the first quarter worth $119,000. Finally, Texas Permanent School Fund bought a new stake in Sucampo Pharmaceuticals during the first quarter worth $197,000. 55.46% of the stock is currently owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals (NASDAQ SCMP) traded up 2.50% during midday trading on Tuesday, reaching $10.25. 92,690 shares of the company’s stock were exchanged. The stock’s market cap is $474.83 million. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $17.55. The firm’s 50-day moving average is $11.61 and its 200 day moving average is $10.71.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.